title: Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders.
abstract: There is a hypothesis that autoimmune abnormalities in neurotransmitter receptors might cause some psychiatric disorders. Using a sensitive radioligand assay, we detected serum autoantibodies to recombinant human muscarinic cholinergic receptor 1 (CHRM1, 34.4%), mu-opioid receptor (OPRM1, 13.1%), 5-hydroxytryptamine receptor 1A (HTR1A, 7.4%), and dopamine receptor D2 (DRD2, 4.9%) in 122 psychiatric patients. Positive antibodies to CHRM1 were found in 34.1%, 34.9%, 33.3%, and 9.1% of patients with schizophrenic disorders (n=44), mood disorders (n=63), other psychiatric disorders (n=15) and autoimmune diseases (n=33), respectively. All three patients with neuroleptic maliganant syndrome had high activities of autoantibodies to CHRM1, OPRM1, and/or HTR1A. Our data suggest that autoimmunity to neurotransmitter receptors might be associated with the induction of psychiatric symptoms and have some relation to neuroleptic malignant syndrome.
authors.affiliation: Department of Laboratory Medicine, Osaka University Graduate School of Medicine (D2), Yamada-oka 2-2, Osaka 565-0871, Suita, Japan. tanaka@labo.med.osaka-u.ac.jp
authors.forename: Susumu
authors.initials: S
authors.lastname: Tanaka
authors.forename: Hidenori
authors.initials: H
authors.lastname: Matsunaga
authors.forename: Masahiro
authors.initials: M
authors.lastname: Kimura
authors.forename: Ke ita
authors.initials: Ki
authors.lastname: Tatsumi
authors.forename: Yoh
authors.initials: Y
authors.lastname: Hidaka
authors.forename: Toru
authors.initials: T
authors.lastname: Takano
authors.forename: Takeshi
authors.initials: T
authors.lastname: Uema
authors.forename: Masatoshi
authors.initials: M
authors.lastname: Takeda
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Amino
mesh_terms: D000328:Adult; D001323:Autoantibodies / Q000096:biosynthesis* / Q000097:blood; D001327:Autoimmune Diseases / Q000276:immunology; D003866:Depressive Disorder / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000276:immunology*; D008875:Middle Aged; D019964:Mood Disorders / Q000276:immunology; D009459:Neuroleptic Malignant Syndrome / Q000276:immunology; D011869:Radioligand Assay; D043643:Receptor, Muscarinic M1; D044282:Receptor, Serotonin, 5-HT1A / Q000276:immunology*; D017448:Receptors, Dopamine D2 / Q000276:immunology*; D011976:Receptors, Muscarinic / Q000276:immunology*; D011957:Receptors, Opioid / Q000276:immunology*; D012559:Schizophrenia / Q000145:classification / Q000276:immunology; D000094942:Nociceptin Receptor
chemical_list: D001323:Autoantibodies; C086088:CHRM1 protein, human; D043643:Receptor, Muscarinic M1; D017448:Receptors, Dopamine D2; D011976:Receptors, Muscarinic; D011957:Receptors, Opioid; D044282:Receptor, Serotonin, 5-HT1A; D000094942:Nociceptin Receptor; C000722283:OPRL1 protein, human